Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00445848 · ClinicalTrials.gov registry record · Phase 2

S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer

A Phase 2 study of Lung Cancer, sponsored by SWOG Cancer Research Network.

Completed
Registry status
Phase 2
Development phase
89
Enrollment target
20
Study locations

NCT00445848 is a Phase 2 study of Lung Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 89 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00445848, a Phase 2 study of Lung Cancer, has completed, sponsored by SWOG Cancer Research Network.

COMPLETED
Registry status
Phase 2
Development phase
89 participants
Enrollment target
20
Study locations

Study Summary

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab also may stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving erlotinib together with bevacizumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving erlotinib together with bevacizumab works in treating patients with stage IIIB or stage IV primary non-small cell lung cancer who have never smoked.

Conditions Studied

Lung Cancer

Interventions

  • BIOLOGICAL bevacizumab
  • DRUG erlotinib hydrochloride

Study Locations (20)

California

  • Kaiser Permanente - Deer Valley - Antioch
  • Alta Bates Summit Comprehensive Cancer Center - Berkeley
  • Peninsula Medical Center - Burlingame
  • Kaiser Permanente - Fremont - Fremont
  • Marin Cancer Institute at Marin General Hospital - Greenbrae
  • Kaiser Permanente Medical Center - Hayward - Hayward
  • Tibotec Therapeutics - Division of Ortho Biotech Products, LP - Marysville
  • Kaiser Permanente Medical Center - Oakland - Oakland
  • Valley Medical Oncology Consultants - Pleasanton - Pleasanton
  • Kaiser Permanente Medical Center - Redwood City - Redwood City
  • Kaiser Permanente Medical Center - Richmond - Richmond
  • Kaiser Permanente Medical Center - Roseville - Roseville
  • University of California Davis Cancer Center - Sacramento
  • South Sacramento Kaiser-Permanente Medical Center - Sacramento
  • Kaiser Permanente Medical Center - Sacramento - Sacramento
  • Kaiser Permanente Medical Center - San Francisco Geary Campus - San Francisco
  • California Pacific Medical Center - California Campus - San Francisco
  • Kaiser Permanente Medical Center - Santa Teresa - San Jose
  • Kaiser Foundation Hospital - San Rafael - San Rafael
  • Sutter Health - Western Division Cancer Research Group - San Rafael

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2007-07
Est. Completion 2014-01
Phase Phase 2

Sponsor

SWOG Cancer Research Network

270 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00445848

The ClinicalTrials.gov registry entry for NCT00445848 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (90% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which bevacizumab is the first listed.

NCT00445848 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00445848 about?

NCT00445848 is a clinical study titled "S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them o...

What is the current status of trial NCT00445848?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2007-07. Estimated completion is 2014-01.

What conditions does trial NCT00445848 study?

This clinical trial studies the following conditions: Lung Cancer.

What interventions are being tested in trial NCT00445848?

The interventions under investigation include: bevacizumab (BIOLOGICAL), erlotinib hydrochloride (DRUG).

Who is sponsoring clinical trial NCT00445848?

This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00445848 being conducted?

This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.